ArticleFrontiers in oncology2026
When the carcinogenic window opens before the screening window: the age-threshold blind spot in early-onset colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-onset colorectal cancer (EOCRC) screening is constrained by a structural blind spot concealed by age-threshold-based eligibility. This limitation does not primarily reflect insufficient screening resources, but rather a fundamental temporal mismatch between screening logic and carcinogenic exposure. High-risk states may be established decades earlier through accumulated early-life "exposure memory," whereas screening triggered by chronological age can intervene only after risk has already been formed. Consequently, individuals younger than 45 years-the population with one of the fastest increases in EOCRC incidence-remain systematically overlooked even after the initiation age for average-risk screening has been lowered to 45 years. This article outlines two parallel pathways: the metabolic-inflammatory axis, including hyperinsulinemia, IGF-1 signaling, and chronic low-grade inflammation; and the gut microbiome axis, including microbial genotoxicity and mucosal immune dysregulation. We clarify how these pathways may encode risk early in life and jointly shift the carcinogenic window forward, making further reductions in age thresholds insufficient for timely identification of truly high-risk young individuals. Accordingly, we argue that EOCRC screening should move from "age-triggered detection" toward "risk-memory recognition." We propose three strategies stratified by clinical readiness: symptom-triggered colonoscopy triage as diagnostic evaluation rather than screening, earlier assessment of exposure memory, and microbiome-informed risk stratification as a research direction. These approaches may help identify high-risk individuals before the conventional screening age and reduce missed diagnoses and diagnostic delays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.